Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red & White

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01642979` - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Phase 2
Active, not recruiting	`NCT01760096` - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Phase 2
Completed	`NCT00592657` - Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions	N/A

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT01642979 - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria

Phase 2

Active, not recruiting

NCT01760096 - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

Phase 2

Completed

NCT00592657 - Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01192425
Study type	Observational
Source	Alexion Pharmaceuticals
Contact
Status	Completed
Phase	N/A

Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes — EXPLORE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms